Operating Lease, Right-of-Use Asset of Enlivex Therapeutics Ltd. from 31 Dec 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Enlivex Therapeutics Ltd. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2019 to 30 Jun 2025.
  • Enlivex Therapeutics Ltd. Operating Lease, Right-of-Use Asset for the quarter ending 30 Jun 2025 was $433,000, a 50% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Enlivex Therapeutics Ltd. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $433,000 -$437,000 -50% 30 Jun 2025 6-K 29 Aug 2025 2025 Q2
Q4 2024 $528,000 -$513,000 -49% 31 Dec 2024 6-K 29 Aug 2025 2025 Q2
Q2 2024 $870,000 -$3,864,000 -82% 30 Jun 2024 6-K 30 Aug 2024 2024 Q2
Q4 2023 $1,041,000 -$3,984,000 -79% 31 Dec 2023 20-F 30 Apr 2025 2024 FY
Q2 2023 $4,734,000 -$635,000 -12% 30 Jun 2023 6-K 01 Sep 2023 2023 Q2
Q4 2022 $5,025,000 -$664,000 -12% 31 Dec 2022 20-F 30 Apr 2024 2023 FY
Q2 2022 $5,369,000 +$4,798,000 +840% 30 Jun 2022 6-K 22 Aug 2022 2022 Q2
Q4 2021 $5,689,000 +$5,030,000 +763% 31 Dec 2021 6-K 22 Aug 2022 2022 Q2
Q2 2021 $571,000 30 Jun 2021 6-K 06 Aug 2021 2021 Q2
Q4 2020 $659,000 +$249,000 +61% 31 Dec 2020 6-K 06 Aug 2021 2021 Q2
Q4 2019 $410,000 31 Dec 2019 20-F 30 Apr 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.